Business
Strong Results, Shaky Stock: A Hives Drug’s Safety Signal Rattles Investors
Celldex’s barzolvolimab cleared chronic hives in about half of patients — data one analyst called the best they’d seen — but two anaphylaxis cases sent the shares down and clouded an otherwise strong readout.